Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB...
October 23 2018 - 8:00AM
VBL Therapeutics (NASDAQ:VBLT), today announced the issuance by the
European Patent Office (EPO) of Patent No. 2908865, a composition
of matter patent which covers VB-111, VBL's lead drug candidate.
The patent provides intellectual property protection for VB-111 in
Europe until October 2033, before any potential extension. The
patent further strengthens the VB-111 intellectual property
portfolio, which comprises multiple granted patents including
composition of matter patents in the US, Japan, China and
additional countries.
“VBL is focused on continually innovating and
advancing cancer treatments,” said Dror Harats, M.D., CEO of VBL
Therapeutics. “This latest patent grant by the EPO further
reinforces our commitment to excellent research and innovation as
well as to protecting our lead candidate, VB-111, which is
currently being investigated in our OVAL Phase 3 trial in
platinum-resistant ovarian cancer."
About Ofranergene Obadenovec
(VB-111)VB-111, a potential first-in-class anticancer
therapeutic candidate, is the Company’s lead oncology product
currently being studied in a Phase 3 trial for ovarian cancer.
VB-111 has received orphan drug designation in both the US and
Europe, and fast track designation in the US for prolongation of
survival in patients with rGBM. In addition, VB-111 successfully
demonstrated proof-of-concept and survival benefit in Phase 2
clinical trials in radioiodine-refractory thyroid cancer and
recurrent platinum-resistant ovarian cancer. VB-111 has received an
Orphan Designation for the treatment of ovarian cancer by the
European Medicines Agency (EMA).
About VBLVascular Biogenics Ltd.,
operating as VBL Therapeutics, is a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of first-in-class treatments for cancer. The
Company’s lead oncology product candidate, ofranergene obadenovec
(VB-111), is a first-in-class, targeted anti-cancer gene-therapy
agent that is positioned to treat a wide range of solid tumors. It
is conveniently administered as an IV infusion once every two
months. It has been observed to be well-tolerated in >300 cancer
patients and demonstrated efficacy signals in an “all comers” Phase
1 trial as well as in three tumor-specific Phase 2 studies.
Ofranergene obadenovec is currently being studied in a Phase 3
trial for platinum-resistant ovarian cancer.
Forward Looking Statements This
press release contains forward-looking statements. All statements
other than statements of historical fact are forward-looking
statements, which are often indicated by terms such as
“anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions. These
forward-looking statements include, but are not limited to,
statements regarding our programs, including VB-111, including
their clinical development, such as the timing thereof, therapeutic
potential and clinical results, and the scope and protection of our
intellectual property rights. These forward-looking statements are
not promises or guarantees and involve substantial risks and
uncertainties. Among the factors that could cause actual results to
differ materially from those described or projected herein include
uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals, the
risk that historical clinical trial results may not be predictive
of future trial results, and that we may not realize the expected
benefits of our intellectual property protection. A further list
and description of these risks, uncertainties and other risks can
be found in the Company’s regulatory filings with the U.S.
Securities and Exchange Commission, including in our annual report
on Form 20-F for the year ended December 31, 2017, and subsequent
filings with the SEC. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. VBL
Therapeutics undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
INVESTOR CONTACT:Michael
RiceLifeSci Advisors, LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024